Solid Biosciences (SLDB) Net Cash Flow (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Net Cash Flow data on file, last reported at $236.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 81.39% year-over-year to $236.6 million; the trailing twelve-month figure through Mar 2026 stood at $85.8 million (down 7.89% YoY), and the FY2025 full-year result was -$20.3 million, down 420.19% from the prior year.
• Net Cash Flow improved to $236.6 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $236.6 million in Q1 2026 to a low of -$77.6 million in Q3 2025.
• A 5-year average of $10.3 million and a median of -$1.4 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 1035.32% in 2022 and slumped 670.37% in 2023, its largest moves.
• Tracing SLDB's Net Cash Flow over 5 years: stood at $106.4 million in 2022, then tumbled by 76.51% to $25.0 million in 2023, then tumbled by 36.5% to $15.9 million in 2024, then slumped by 108.81% to -$1.4 million in 2025, then jumped by 17020.96% to $236.6 million in 2026.
• Business Quant data shows SLDB's Net Cash Flow at $236.6 million in Q1 2026, -$1.4 million in Q4 2025, and -$77.6 million in Q3 2025.